This page collects WhisperX intelligence signals tagged #weight loss. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
The U.S. Food and Drug Administration (FDA) has taken regulatory action against 30 telehealth companies, issuing formal warning letters concerning their marketing and promotion of compounded versions of popular glucagon-like peptide-1 (GLP-1) agonist drugs, such as Ozempic (semaglutide) and Zepbound (tirzepatide). The ...
The U.S. Food and Drug Administration (FDA) is escalating its enforcement campaign against the compounding of GLP-1 receptor agonist drugs, such as semaglutide and tirzepatide, which are widely used for weight loss and diabetes. In a significant move, the agency has issued a fresh batch of 30 warning letters to telehea...